Pharma Equity Group ASOCSE:PEG Market Cap is kr105.57 Mil as of Jul. 01, 2026. The stock has 3 warning signs investors should review. Among 1,427 Biotechnology companies, Pharma Equity Group AS ranks worse than 78.98% on this metric.
Pharma Equity Group AS's quarterly market cap
declined
from Dec. 2024 (kr233.23 Mil) to Jun. 2025 (kr149.76 Mil) and
declined
from Jun. 2025 (kr149.76 Mil) to Dec. 2025 (kr114.65 Mil).
Pharma Equity Group AS's annual market cap
declined
from Dec. 2023 (kr439.87 Mil) to Dec. 2024 (kr233.23 Mil) and
declined
from Dec. 2024 (kr233.23 Mil) to Dec. 2025 (kr114.65 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pharma Equity Group AS's Enterprise Value for Today is kr113.13 Mil.
Pharma Equity Group AS (OCSE:PEG) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:PEG vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Pharma Equity Group AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Equity Group AS Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's Market Cap distribution charts can be found below:
* The bar in red indicates where Pharma Equity Group AS's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Pharma Equity Group AS's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Equity Group AS (OCSE:PEG) has a Market Cap of kr105.57 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pharma Equity Group AS and its competitors. According to the industry distribution chart, Pharma Equity Group AS ranks #1127 out of 1427 companies in the Biotechnology industry, placing it in the top 79%.
Is Pharma Equity Group AS's Market Cap too high?
Pharma Equity Group AS's current Market Cap is kr105.57 Mil. Based on the distribution chart, Pharma Equity Group AS ranks #1127 out of 1427 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Pharma Equity Group AS's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #1127 out of 1427 companies for Market Cap. This places Pharma Equity Group AS in the lower half of its industry. The industry median Market Cap is 119.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pharma Equity Group AS and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Equity Group AS's current Market Cap is kr105.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current Market Cap of kr105.57 Mil. The current Market Cap is kr105.57 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current Market Cap is kr105.57 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:PEG has been successfully added to your 